Clinical Scorecard: Distinct yet Overlapping Functions of TLR7 and TLR9 in Systemic Lupus Erythematosus and Sjögren’s Syndrome
At a Glance
Category
Detail
Condition
Key Mechanisms
Target Population
Individuals with SLE and SjD, predominantly women of reproductive age, including those of African origin.
Care Setting
Key Highlights
SLE affects approximately 3.4 million individuals worldwide, with 400,000 new cases annually, and is most prevalent among women of reproductive age, especially those of African descent.
SjD has a notable female predilection and affects 0.01 – 0.05% of the population, with extra-glandular manifestations in 30-50% of patients.
Both SLE and SjD are characterized by heightened TLR7 and TLR9 activation, with significant implications for sex-biased organ-specific manifestations.
Aberrant TLR signaling contributes to disease pathogenesis in both conditions, with SNPs in TLR7 and TLR9 identified as risk factors.
Emerging therapies targeting TLR pathways show potential for treatment.
Guideline-Based Recommendations
Diagnosis
Identify clinical manifestations and autoantibody profiles associated with SLE and SjD, including anti-nuclear antibodies (ANA) and anti-Ro/La antibodies.
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients diagnosed with SLE and SjD, particularly women.
Current and emerging therapies targeting endosomal TLR pathways may improve outcomes.
Clinical Best Practices
Utilize genetic testing to identify risk factors for SLE and SjD, particularly SNPs in TLR7 and TLR9.
Implement a multidisciplinary approach for managing organ-specific manifestations.
Educate patients on the importance of monitoring symptoms and treatment adherence.
A VHA study across 11 vendors finds AI-generated primary care notes score lower than clinician-written notes, with the largest deficits in thoroughness, organization, and usefulness
